UnitedHealth's shares soared 11% in a single day, while Humana climbed 9%, following a surprising decision by the Centers for Medicare & Medicaid Services (CMS) to raise Medicare Advantage payments for 2027 well above expectations. This decision shook up the managed care sector and gave investors some relief after months of worry.
Medicare Advantage Payments Get a Bigger Boost Than Expected
Last week, CMS finalized a 2.48% increase to payments for Medicare Advantage plans in 2027, surpassing the initial proposal that had suggested a near-flat increase of just 0.09%. When factoring in risk-score trends, the average payment hike jumps to nearly 5%. This was a big surprise compared to what the market expected.
The decision means insurers providing these private plans can expect over $13 billion more in federal payments next year, a welcome relief for companies caught off guard by earlier cost-cutting warnings. The Medicare Advantage program, which covers nearly half of all Medicare beneficiaries, has been under pressure lately as regulators considered updates to risk-adjustment models that could have slashed payments.
CMS’s choice to hold off on those changes signals a more cautious approach, giving the market time to adjust while preventing a sudden hit to insurer margins. However, with medical costs rising, it’s still unclear how much this will help profits.
UnitedHealth Leads the Rally with Its Scale and Optum Integration
That said, unitedHealth Group, the largest Medicare Advantage insurer by enrollment, reacted sharply to the news. Shares opened at $281 but quickly climbed above $310 during trading, marking their biggest intraday jump since August.
The stock had been battered earlier this year, down more than 14% due to concerns over rising costs, a costly cyberattack, and regulatory woes.
But the CMS announcement shifts the outlook. UnitedHealth’s scale and its integrated healthcare services platform, Optum, put it in a strong position to capitalize on the higher rates despite some near-term membership losses. The company had forecast revenue topping $439 billion and adjusted earnings above $17.75 per share for 2026—targets that now seem more attainable.
Analysts quickly adjusted their views. Bank of America raised its price target for UnitedHealth from $315 to $337, while the broader analyst consensus leans bullish, with most recommending buys and expecting the stock to reach around $358 on average.
Humana’s Stock Jumps as Wells Fargo Backs the Upside
Humana, another major player in the Medicare Advantage space, saw its shares advance about 9%, climbing from $182 to just under $200. The company faced even steeper challenges earlier in the year, with investors worried about regulatory headwinds and financial pressures.
Wells Fargo’s recent upgrade of Humana’s stock added fuel to the rally, as investors now see better reimbursement as a key driver for margin recovery. The 2.48% CMS rate increase is more than double what was initially proposed, easing fears of a major cutback in government payments.
Like UnitedHealth, Humana’s business depends heavily on fixed monthly payments from the government for each enrollee in Medicare Advantage plans. This boost in rates translates directly into higher revenue, which could help offset rising medical costs and support profitability in the coming years.
Broader Impact on Managed Care Stocks and Industry Outlook
The rally didn’t stop with UnitedHealth and Humana. Other managed care providers like CVS Health also saw their shares jump sharply, with CVS gaining nearly 7% intraday. Investors appear to be recalibrating expectations across the sector, anticipating improved revenue and earnings potential heading into 2027.
For months, the managed care industry had been on edge. A combination of regulatory uncertainty, rising medical expenses, and other challenges had driven many stock prices down. The CMS’s latest move interrupts that trend, offering a financial cushion that insurers badly needed.
Still, the industry has challenges ahead. Medical inflation remains a pressing issue, and regulators will keep a close eye on payment accuracy and market sustainability. The decision to delay changes in the risk-adjustment model suggests CMS wants to avoid shocks but also hints that future adjustments could be on the horizon.
Investors are keeping a close eye on how this all unfolds. The new payment rates provide a runway for insurers to stabilize margins, but they don’t eliminate the complexities of managing healthcare costs and regulatory demands.
Meanwhile, the Medicare Advantage program itself continues to grow rapidly, attracting more seniors with its comprehensive coverage options. That growth is a key reason why federal payment levels are so influential for insurers’ financial health.
UnitedHealth and Humana stand to benefit the most from this trend, given their dominant market shares. But the wider managed care field will also feel the impact, potentially reshaping competition and investment strategies going forward.
The CMS’s decision to raise Medicare Advantage payments by 2.48% for 2027 has sparked a powerful rally in managed care stocks, with UnitedHealth and Humana leading the charge. While it doesn’t erase all concerns about rising costs and regulatory risk, it provides a much-needed boost to insurers facing a challenging environment. Now, it’s up to these companies to use this opportunity to handle the tough healthcare environment.
